[시장보고서]세계의 류마티스 관절염 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

세계의 류마티스 관절염 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Rheumatoid Arthritis Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1660929

리서치사 : Persistence Market Research

발행일 : 2025년 02월

페이지 정보 : 영문 211 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,461,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,897,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,689,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 류마티스 관절염 시장 규모는 2025년에 7억9,990만 달러에 달하고, 2025년-2032년의 예측 기간 동안 5.5%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 2032년에는 11억 6,360만 달러에 달할 것으로 예측되고 있습니다.

류마티스 관절염은 주로 관절을 침범하고 염증, 통증, 진행성 관절 손상을 일으키는 만성자가 면역 질환입니다. 류마티스 관절염 치료제 시장에는 생물학적 제제, 질병 변형성 류마티스 약물(DMARD), 비스테로이드성 항염증제(NSAID), 부신 피질 스테로이드 약물 등의 광범위한 약물이 포함됩니다. 주요 치료 환경으로는 병원, 전문 클리닉, 가정 의료 등이 있으며, 환자는 약물 요법과 비 약물 요법을 모두 받고 있습니다. 시장 성장의 원동력은 유병률 증가, 인지도의 향상, 생물학적 치료의 진보, 헬스케어 접근의 개선입니다.

세계 류마티스 관절염 시장은 자가면역 질환의 이환율 증가, 인구 고령화, 조기 진단 및 치료 옵션에 대한 환자 의식 증가 등 여러 요인에 의해 추진되고 있습니다. 류마티스 관절염의 증상을 관리하고 질병 진행을 늦추는 효과를 높이는 생물학적 제제와 표적 합성 DMARD의 채용이 증가하고 있는 것도 시장 확대에 크게 기여하고 있습니다. 또한, 장시간 작용하는 주사제 및 피하 투여 제제와 같은 약물 전달 시스템의 기술적 진보로 환자의 컴플라이언스와 치료 성적이 향상되었습니다. 개인화된 의료 역할의 확대와 RA 치료에 대한 접근성을 개선하기 위한 정부의 이니셔티브는 시장 성장을 더욱 강화하고 있습니다.

류마티스 관절염 시장은 바이오시밀러의 진보, 새로운 표적 치료제의 연구 증가, 환자 모니터링을 위한 디지털 건강 솔루션의 통합 등을 통해 큰 성장 기회를 제공합니다. 인공지능을 이용한 신약, 병용 요법 및 줄기 세포 치료를 포함한 재생 의학 접근법과 같은 새로운 동향은 류마티스 관절염 치료에서 획기적인 잠재력을 제공합니다. 제약회사와 연구기관의 전략적 제휴가 혁신을 촉진하고, 원격의료 및 디지털 치료에 대한 액세스 확대가 질병 관리를 개선하고 있습니다. 게다가 라이프스타일 개선, 홀리스틱 치료 접근법, 환자 중심 케어모델에 대한 주목이 높아짐에 따라 시장 진출기업이 제품 제공을 강화하고 보다 폭넓은 환자층에 접근할 수 있는 새로운 길을 열고 있습니다.

이 보고서는 세계 류마티스 관절염 시장을 조사했으며, 검사 유형별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

경쟁 대시보드
브랜딩 및 프로모션 전략
주요 개발 분석
경쟁의 상세
- Abbott Diagnostics
- Antibodies Incorporated
- Beckman Coulter, Inc.
- Euro Diagnostica AB
- Thermo Fisher Scientific Inc.
- Qiagen NV
- F. Hoffmann-La Roche Ltd.
- Siemens Healthcare GmbH
- Janel Group(Antibodies Inc.)

제20장 사용된 전제조건과 약어

제21장 조사 방법

SHW

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for rheumatoid arthritis (RA). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global rheumatoid arthritis market from 2025 to 2032.

Key Insights:

Rheumatoid Arthritis Market Size (2025E): USD 799.9 Million
Projected Market Value (2032F): USD 1,163.6 Million
Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Rheumatoid Arthritis Market - Report Scope:

Rheumatoid arthritis is a chronic autoimmune disease that primarily affects joints, leading to inflammation, pain, and progressive joint damage. The market for RA treatment includes a wide range of drugs such as biologics, disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. Key treatment settings include hospitals, specialty clinics, and homecare settings, where patients receive both pharmacological and non-pharmacological therapies. Market growth is driven by increasing prevalence, rising awareness, advancements in biologic therapies, and improved healthcare access.

Market Growth Drivers:

The global rheumatoid arthritis market is propelled by multiple factors, including the rising incidence of autoimmune disorders, aging populations, and growing patient awareness regarding early diagnosis and treatment options. The increasing adoption of biologic and targeted synthetic DMARDs, which offer enhanced efficacy in managing RA symptoms and slowing disease progression, significantly contributes to market expansion. Additionally, technological advancements in drug delivery systems, such as long-acting injectables and subcutaneous formulations, are improving patient compliance and treatment outcomes. The expanding role of personalized medicine, along with government initiatives to improve access to RA treatments, further supports market growth.

Market Restraints:

Despite promising growth prospects, the rheumatoid arthritis market faces challenges, including the high cost of biologic drugs, limited healthcare access in low-income regions, and the risk of adverse effects associated with long-term RA treatments. Patent expirations of leading biologics are leading to increased competition from biosimilars, which, while enhancing affordability, may also impact the revenues of key market players. Additionally, stringent regulatory requirements and reimbursement constraints can pose barriers to market expansion, particularly in emerging economies with limited healthcare infrastructure.

Market Opportunities:

The rheumatoid arthritis market presents significant growth opportunities driven by advancements in biosimilars, increasing research into novel targeted therapies, and the integration of digital health solutions for patient monitoring. Emerging trends such as AI-driven drug discovery, combination therapies, and regenerative medicine approaches, including stem cell therapies, offer potential breakthroughs in RA treatment. Strategic collaborations between pharmaceutical companies and research institutions are fostering innovation, while expanding access to telemedicine and digital therapeutics is improving disease management. Furthermore, the growing focus on lifestyle modifications, holistic treatment approaches, and patient-centric care models is opening new avenues for market players to enhance their product offerings and reach a broader patient population.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the rheumatoid arthritis market globally?
Which drug classes and treatment approaches are shaping the future of RA management?
How are biosimilars influencing the competitive landscape of the rheumatoid arthritis market?
Who are the key players contributing to market growth, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global rheumatoid arthritis market?

Competitive Intelligence and Business Strategy:

Leading players in the global rheumatoid arthritis market, including AbbVie Inc., Pfizer Inc., Amgen Inc., and Johnson & Johnson, are focusing on innovation, strategic collaborations, and product differentiation to maintain a competitive edge. These companies are investing in R&D for next-generation biologics, biosimilars, and targeted therapies to improve treatment outcomes. Collaborations with healthcare providers and regulatory agencies are facilitating market access and promoting technology adoption. Additionally, increasing investments in digital health platforms, patient education, and clinical trials for novel drug candidates are shaping the competitive landscape of the RA market.

Key Companies Profiled:

AbbVie Inc.
Pfizer Inc.
Amgen Inc.
Johnson & Johnson
Eli Lilly and Company
Bristol-Myers Squibb Company
Sanofi S.A.
Roche Holding AG
Novartis AG
UCB S.A.

Key Segments Covered in Rheumatoid Arthritis Industry Research

Test Type

Serology Tests
Monitoring rheumatoid arthritis Treatment Efficiency Tests

End User

Hospitals
Diagnostic Laboratories
Ambulatory Surgical Centers

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends

4. Key Success Factors

4.1. Adoption Analysis
4.2. Key Regulations
4.3. Cost Analysis, By Test Type
4.4. Reimbursement Scenario
4.5. Supply Chain Analysis
4.6. PESTLE Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Autoimmune Disease Diagnostics Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Growing Healthcare Expenditure
- 5.2.2. Increasing Adoption of Rheumatoid Arthritis Diagnostic Tests
- 5.2.3. Prevalence of Arthritis Diseases
- 5.2.4. New Product Launches
- 5.2.5. Adoption of Off-Label Arthritis Diagnostic Procedures
- 5.2.6. Increasing Research Activities to Expand Diagnostic Methods
- 5.2.7. Study of Limited Specificity and Sensitivity of Rheumatoid Arthritis Test Kits
- 5.2.8. Growing Awareness about Chronic Diseases
- 5.2.9. Government Funding and Initiatives
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Test Type
- 6.1.2. By End User
- 6.1.3. By Country
6.2. 2022 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019 - 2032

7.1. Historical Market Value (US$ Mn) Analysis, 2019 - 2024
7.2. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019 - 2032, By Test Type

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2019 - 2024
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Test Type, 2025 - 2032
- 8.3.1. Serology Test
  - 8.3.1.1. Erythrocyte Sedimentation Rate (ESR)
  - 8.3.1.2. Rheumatoid Factor (RF)
  - 8.3.1.3. Anti-cyclic Citrullinated Peptide (anti-CCP)
  - 8.3.1.4. Antinuclear Antibody (ANA)
  - 8.3.1.5. Uric Acid
  - 8.3.1.6. Other Test
- 8.3.2. Monitoring RA Treatment Efficiency Tests
  - 8.3.2.1. Salicylate Level Count
  - 8.3.2.2. Muscle Enzyme Test
  - 8.3.2.3. Creatinine Test
8.4. Market Attractiveness Analysis By Test Type

9. Global Market Analysis 2019 - 2032, By End User

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis by End User, 2019 - 2024
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2025 - 2032
- 9.3.1. Hospitals
- 9.3.2. Diagnostic Laboratories
  - 9.3.2.1. Private Laboratories
  - 9.3.2.2. Public Laboratories
- 9.3.3. Ambulatory Surgical Centers
9.4. Market Attractiveness Analysis by End User

10. Global Market Analysis 2019 - 2032, By Region

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019 - 2024
10.3. Current and Future Market Size (US$ Mn) Analysis Forecast by Region, 2025 - 2032
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis by Region

11. North America Market Analysis 2019 - 2032

11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 11.3.1. By Country
  - 11.3.1.1. U.S.
  - 11.3.1.2. Canada
- 11.3.2. By Test Type
- 11.3.3. By End User
11.4. Market Attractiveness Analysis
- 11.4.1. By Country
- 11.4.2. By Test Type
- 11.4.3. By End User
11.5. Market Trends
11.6. Key Market Participants - Intensity Mapping
11.7. Drivers and Restraints - Impact Analysis
11.8. Country Level Analysis & Forecast
- 11.8.1. U.S. Market
  - 11.8.1.1. Introduction
  - 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.1.2.1. By Test Type
    - 11.8.1.2.2. By End User
- 11.8.2. Canada Market
  - 11.8.2.1. Introduction
  - 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.2.2.1. By Test Type
    - 11.8.2.2.2. By End User

12. Latin America Market Analysis 2019 - 2032

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 12.3.1. By Country
  - 12.3.1.1. Mexico
  - 12.3.1.2. Brazil
  - 12.3.1.3. Argentina
  - 12.3.1.4. Rest of Latin America
- 12.3.2. By Test Type
- 12.3.3. By End User
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Test Type
- 12.4.3. By End User
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
- 12.8.1. Mexico Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Test Type
    - 12.8.1.2.2. By End User
- 12.8.2. Brazil Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Test Type
    - 12.8.2.2.2. By End User
- 12.8.3. Argentina Market Analysis
  - 12.8.3.1. Introduction
  - 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.3.2.1. By Test Type
    - 12.8.3.2.2. By End User

13. Europe Market Analysis 2019 - 2032

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 13.3.1. By Country
  - 13.3.1.1. Germany
  - 13.3.1.2. Italy
  - 13.3.1.3. France
  - 13.3.1.4. U.K.
  - 13.3.1.5. Spain
  - 13.3.1.6. BENELUX
  - 13.3.1.7. Russia
  - 13.3.1.8. Rest of Europe
- 13.3.2. By Test Type
- 13.3.3. By End User
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Test Type
- 13.4.3. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. Germany Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Test Type
    - 13.8.1.2.2. By End User
- 13.8.2. Italy Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Test Type
    - 13.8.2.2.2. By End User
- 13.8.3. France Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Test Type
    - 13.8.3.2.2. By End User
- 13.8.4. U.K. Market Analysis
  - 13.8.4.1. Introduction
  - 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.4.2.1. By Test Type
    - 13.8.4.2.2. By End User
- 13.8.5. Spain Market Analysis
  - 13.8.5.1. Introduction
  - 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.5.2.1. By Test Type
    - 13.8.5.2.2. By End User
- 13.8.6. BENELUX Market Analysis
  - 13.8.6.1. Introduction
  - 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.6.2.1. By Test Type
    - 13.8.6.2.2. By End User
- 13.8.7. Russia Market Analysis
  - 13.8.7.1. Introduction
  - 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.7.2.1. By Test Type
    - 13.8.7.2.2. By End User

14. East Asia Market Analysis 2019 - 2032

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 14.3.1. By Country
  - 14.3.1.1. China
  - 14.3.1.2. Japan
  - 14.3.1.3. South Korea
- 14.3.2. By Test Type
- 14.3.3. By End User
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Test Type
- 14.4.3. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. China Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Test Type
    - 14.8.1.2.2. By End User
- 14.8.2. Japan Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Test Type
    - 14.8.2.2.2. By End User
- 14.8.3. South Korea Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Test Type
    - 14.8.3.2.2. By End User

15. South Asia Market Analysis 2019 - 2032

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 15.3.1. By Country
  - 15.3.1.1. India
  - 15.3.1.2. Indonesia
  - 15.3.1.3. Malaysia
  - 15.3.1.4. Thailand
  - 15.3.1.5. Rest of South Asia
- 15.3.2. By Test Type
- 15.3.3. By End User
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Test Type
- 15.4.3. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. India Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Test Type
    - 15.8.1.2.2. By End User
- 15.8.2. Indonesia Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Test Type
    - 15.8.2.2.2. By End User
- 15.8.3. Malaysia Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Test Type
    - 15.8.3.2.2. By End User
- 15.8.4. Thailand Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Test Type
    - 15.8.4.2.2. By End User

16. Oceania Market 2019 - 2032

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 16.3.1. By Country
  - 16.3.1.1. Australia
  - 16.3.1.2. New Zealand
- 16.3.2. By Test Type
- 16.3.3. By End User
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Test Type
- 16.4.3. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. Australia Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Test Type
    - 16.8.1.2.2. By End User
- 16.8.2. New Zealand Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Test Type
    - 16.8.2.2.2. By End User

17. Middle East and Africa (MEA) Market Analysis 2019 - 2032

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
- 17.3.1. By Country
  - 17.3.1.1. GCC Countries
  - 17.3.1.2. Turkiye
  - 17.3.1.3. North Africa
  - 17.3.1.4. South Africa
  - 17.3.1.5. Rest of Middle East and Africa
- 17.3.2. By Test Type
- 17.3.3. By End User
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Test Type
- 17.4.3. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. GCC Countries Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Test Type
    - 17.8.1.2.2. By End User
- 17.8.2. Turkiye Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Test Type
    - 17.8.2.2.2. By End User
- 17.8.3. South Africa Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Test Type
    - 17.8.3.2.2. By End User
- 17.8.4. North Africa Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Test Type
    - 17.8.4.2.2. By End User

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis

19. Competition Analysis

19.1. Competition Dashboard
19.2. Branding and Promotional Strategies
19.3. Key Development Analysis
19.4. Competition Deep Dive
- 19.4.1. Abbott Diagnostics
  - 19.4.1.1. Overview
  - 19.4.1.2. Service Portfolio
  - 19.4.1.3. Sales Footprint
  - 19.4.1.4. Key Financials
  - 19.4.1.5. SWOT Analysis
  - 19.4.1.6. Strategy Overview
    - 19.4.1.6.1. Marketing Strategy
    - 19.4.1.6.2. Diagnostic Test Strategy
    - 19.4.1.6.3. Channel Strategy
- 19.4.2. Antibodies Incorporated
  - 19.4.2.1. Overview
  - 19.4.2.2. Service Portfolio
  - 19.4.2.3. Sales Footprint
  - 19.4.2.4. Key Financials
  - 19.4.2.5. SWOT Analysis
  - 19.4.2.6. Strategy Overview
    - 19.4.2.6.1. Marketing Strategy
    - 19.4.2.6.2. Diagnostic Test Strategy
    - 19.4.2.6.3. Channel Strategy
- 19.4.3. Beckman Coulter, Inc.
  - 19.4.3.1. Overview
  - 19.4.3.2. Service Portfolio
  - 19.4.3.3. Sales Footprint
  - 19.4.3.4. Key Financials
  - 19.4.3.5. SWOT Analysis
  - 19.4.3.6. Strategy Overview
    - 19.4.3.6.1. Marketing Strategy
    - 19.4.3.6.2. Diagnostic Test Strategy
    - 19.4.3.6.3. Channel Strategy
- 19.4.4. Euro Diagnostica AB
  - 19.4.4.1. Overview
  - 19.4.4.2. Service Portfolio
  - 19.4.4.3. Sales Footprint
  - 19.4.4.4. Key Financials
  - 19.4.4.5. SWOT Analysis
  - 19.4.4.6. Strategy Overview
    - 19.4.4.6.1. Marketing Strategy
    - 19.4.4.6.2. Diagnostic Test Strategy
    - 19.4.4.6.3. Channel Strategy
- 19.4.5. Thermo Fisher Scientific Inc.
  - 19.4.5.1. Overview
  - 19.4.5.2. Service Portfolio
  - 19.4.5.3. Sales Footprint
  - 19.4.5.4. Key Financials
  - 19.4.5.5. SWOT Analysis
  - 19.4.5.6. Strategy Overview
    - 19.4.5.6.1. Marketing Strategy
    - 19.4.5.6.2. Diagnostic Test Strategy
    - 19.4.5.6.3. Channel Strategy
- 19.4.6. Qiagen N.V.
  - 19.4.6.1. Overview
  - 19.4.6.2. Service Portfolio
  - 19.4.6.3. Sales Footprint
  - 19.4.6.4. Key Financials
  - 19.4.6.5. SWOT Analysis
  - 19.4.6.6. Strategy Overview
    - 19.4.6.6.1. Marketing Strategy
    - 19.4.6.6.2. Diagnostic Test Strategy
    - 19.4.6.6.3. Channel Strategy
- 19.4.7. F. Hoffmann-La Roche Ltd.
  - 19.4.7.1. Overview
  - 19.4.7.2. Service Portfolio
  - 19.4.7.3. Sales Footprint
  - 19.4.7.4. Key Financials
  - 19.4.7.5. SWOT Analysis
  - 19.4.7.6. Strategy Overview
    - 19.4.7.6.1. Marketing Strategy
    - 19.4.7.6.2. Diagnostic Test Strategy
    - 19.4.7.6.3. Channel Strategy
- 19.4.8. Siemens Healthcare GmbH
  - 19.4.8.1. Overview
  - 19.4.8.2. Service Portfolio
  - 19.4.8.3. Sales Footprint
  - 19.4.8.4. Key Financials
  - 19.4.8.5. SWOT Analysis
  - 19.4.8.6. Strategy Overview
    - 19.4.8.6.1. Marketing Strategy
    - 19.4.8.6.2. Diagnostic Test Strategy
    - 19.4.8.6.3. Channel Strategy
- 19.4.9. Janel Group (Antibodies Inc.)
  - 19.4.9.1. Overview
  - 19.4.9.2. Service Portfolio
  - 19.4.9.3. Sales Footprint
  - 19.4.9.4. Key Financials
  - 19.4.9.5. SWOT Analysis
  - 19.4.9.6. Strategy Overview
    - 19.4.9.6.1. Marketing Strategy
    - 19.4.9.6.2. Diagnostic Test Strategy
    - 19.4.9.6.3. Channel Strategy

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 주요 시장 동향

제4장 중요한 성공 요인

제5장 시장 배경

제6장 COVID-19 위기 분석

제7장 세계 시장 수요(가치 또는 규모, 100만 달러) 분석, 2019년-2032년

제8장 세계 시장 분석, 2019년-2032년, 검사 유형별

제9장 세계 시장 분석, 2019년-2032년, 최종 사용자별

제10장 세계 시장 분석, 2019년-2032년, 지역별

제11장 북미 시장 분석, 2019년-2032년

제12장 라틴아메리카 시장 분석, 2019년-2032년

제13장 유럽 시장 분석, 2019년-2032년

제14장 동아시아 시장 분석, 2019년-2032년

제15장 남아시아 시장 분석, 2019년-2032년

제16장 오세아니아 시장 분석, 2019년-2032년

제17장 중동 및 아프리카 시장 분석, 2019년-2032년

제18장 시장 구조 분석

제19장 경쟁 분석